Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Jung, Chang H ^a   Lee, Min J ^a   Kang, Yu M ^a   Lee, Yoo L ^a   Yoon, Hae K ^a   Kang, Sang Wook ^a   Lee, Woo J ^a   Park, Joong Yeol ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adhesion molecules; AMPK; Endothelial cells; NF B; Vaspin

Indexed keywords

AMP-ACTIVATED PROTEIN KINASES; CELL ADHESION MOLECULES; CELLS, CULTURED; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; NF-KAPPA B; SERPINS;

EID: 84893647250     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-41     Document Type: Article

References (54)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138(5 Pt 2):S419-420.
2. Schiffrin EL, Canadian Institutes of Health Research Multidisciplinary Research Group on H Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002, 15(10 Pt 2):115S-122S. Canadian Institutes of Health Research Multidisciplinary Research Group on H.
3. Allan LG. Is there a constant minimum perceptual duration?. Q J Exp Psychol 1976, 28(1):71-76. 10.1080/14640747608400539, 1273252.
4. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 2003, 9(12):549-557. 10.1016/j.molmed.2003.10.007, 14659470.
5. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(11):2292-2301. 10.1161/ATVBAHA.107.149179, 17673705.
6. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996, 97(7):1715-1722. 10.1172/JCI118598, 507236, 8601637.
7. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997, 82(2):297-304.
8. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997, 272(25):15817-15824. 10.1074/jbc.272.25.15817, 9188479.
9. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky MI. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999, 85(2):199-207. 10.1161/01.RES.85.2.199, 10417402.
10. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394(6696):894-897. 10.1038/29788, 9732872.
11. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107(3):255-264. 10.1172/JCI10373, 199202, 11160146.
12. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251(4995):788-791. 10.1126/science.1990440, 1990440.
13. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51(7):2074-2081. 10.2337/diabetes.51.7.2074, 12086935.
14. Zou MH, Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008, 35(5-6):535-545. 2869205, 18177481.
15. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47(6):1183-1188. 10.1161/01.HYP.0000221429.94591.72, 16636195.
16. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011, 34(3):307-310. 10.1248/bpb.34.307, 21372376.
17. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102(30):10610-10615. 10.1073/pnas.0504703102, 1180799, 16030142.
18. Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, Lee YL, Kim HS, Kim MS, Park JY. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLos One 2012, 7(12):e52346. 10.1371/journal.pone.0052346, 3532208, 23284999.
19. Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 2011, 413(2):264-269. 10.1016/j.bbrc.2011.08.083, 21893030.
20. Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, et al. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 2012, 61(11):2823-2832. 10.2337/db12-0232, 3478540, 22837305.
21. Hattori Y, Suzuki M, Hattori S, Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 2002, 39(1):22-28. 10.1161/hy1201.097300, 11799073.
22. Iwai K. Diverse ubiquitin signaling in NF-kappaB activation. Trends Cell Biol 2012, 22(7):355-364. 10.1016/j.tcb.2012.04.001, 22543051.
23. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 2002, 41(43):12995-13002. 10.1021/bi0263210, 12390026.
24. Bess E, Fisslthaler B, Fromel T, Fleming I. Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells. PLos One 2011, 6(6):e20848. 10.1371/journal.pone.0020848, 3108981, 21673972.
25. Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD. The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 1998, 140(3):371-377. 10.1007/s002130050778, 9877017.
26. Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, et al. Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ Res 2013, 112(5):771-780. 10.1161/CIRCRESAHA.111.300049, 23307819.
27. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004, 117(Pt 23):5479-5487.
28. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 2002, 92(6):2475-2482.
29. Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res 2011, 64(5):493-500. 10.1016/j.phrs.2011.06.001, 21683791.
30. Li H, Peng W, Zhuang J, Lu Y, Jian W, Wei Y, Li W, Xu Y. Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappaB signaling pathways. Atherosclerosis 2013, 228(1):61-68. 10.1016/j.atherosclerosis.2013.02.013, 23497782.
31. Sung JY, Choi HC. Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway. Vascul Pharmacol 2012, 56(1-2):1-8.
32. Kim HJ, Park KG, Yoo EK, Kim YH, Kim YN, Kim HS, Kim HT, Park JY, Lee KU, Jang WG, et al. Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid Redox Signal 2007, 9(3):301-307. 10.1089/ars.2006.1456, 17184171.
33. Chandrasekar B, Boylston WH, Venkatachalam K, Webster NJ, Prabhu SD, Valente AJ. Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem 2008, 283(36):24889-24898. 10.1074/jbc.M804236200, 3259831, 18632660.
34. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010, 106(6):1117-1128. 10.1161/CIRCRESAHA.109.212530, 2920052, 20167927.
35. Li Z, Zhong Q, Yang T, Xie X, Chen M. The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc Diabetol 2013, 12:141. 10.1186/1475-2840-12-141, 3817312, 24090212.
36. Zhu M, Chen J, Jiang H, Miao C. Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells. Cardiovasc Diabetol 2013, 12:13. 10.1186/1475-2840-12-13, 3579710, 23311470.
37. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000, 346(Pt 3):659-669. 1220898, 10698692.
38. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999, 24(1):22-25. 10.1016/S0968-0004(98)01340-1, 10087918.
39. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55(2):496-505. 10.2337/diabetes.55.02.06.db05-1064, 16443786.
40. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004, 279(42):43940-43951. 10.1074/jbc.M404421200, 15265871.
41. Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection?. Curr Opin Pharmacol 2009, 9(2):202-207. 10.1016/j.coph.2008.10.005, 19081303.
42. Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol 2013, 4:97.
43. Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol 2013, 209(3):212-219.
44. Phalitakul S, Okada M, Hara Y, Yamawaki H. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 423(4):844-849. 10.1016/j.bbrc.2012.06.052, 22713468.
45. Cho JK, Han TK, Kang HS. Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol 2010, 108(2):347-353. 10.1007/s00421-009-1238-8, 19816707.
46. Kim JM, Kim TN, Won JC. Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab Syndr Relat Disord 2013, 11(6):385-391. 10.1089/met.2013.0054, 23992351.
47. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J 2011, 58(4):237-246. 10.1507/endocrj.K10E-330, 21325745.
48. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008, 57(6):1501-1507. 10.2337/db08-0127, 18375437.
49. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57(2):372-377.
50. Zhang B, Peng W, Li H, Lu Y, Zhuang J, Wang K, Su Y, Xu Y. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin Biochem 2013, 46(15):1520-1525. 10.1016/j.clinbiochem.2013.06.028, 23850850.
51. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf) 2011, 75(5):628-635. 10.1111/j.1365-2265.2011.04095.x, 21545478.
52. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011, 412(1-2):48-52. 10.1016/j.cca.2010.09.012, 20850423.
53. Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, et al. Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab 2012, 97(7):E1202-1207. 10.1210/jc.2011-3297, 22539588.
54. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17(3):327-333. 10.1517/13543784.17.3.327, 18321232.